The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of <i>ALK</i>-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Here, ALK is linked to metabolic syndrome.